These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36305947)

  • 1. Developing an effective quality evaluation strategy of next-generation sequencing for accurate detecting non-small cell lung cancer samples with variable characteristics: a real-world clinical practice.
    Rao W; Guo L; Ling Y; Dong L; Li W; Ying J; Li W
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4889-4897. PubMed ID: 36305947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
    Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
    Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical next-generation sequencing in patients with non-small cell lung cancer.
    Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
    Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Actionable mutational profiling in solid tumors using hybrid-capture-based next-generation sequencing in a real-world setting in Spain.
    Zazo S; Pérez-Buira S; Carvajal N; Plaza-Sánchez J; Manso R; Pérez-González N; Dominguez C; Prieto-Potin I; Rubio J; Dómine M; Lozano V; Mohedano P; Carcedo D; Carias R; Rojo F
    Cancer Med; 2024 Feb; 13(3):e6827. PubMed ID: 38213074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform.
    Vanni I; Coco S; Truini A; Rusmini M; Dal Bello MG; Alama A; Banelli B; Mora M; Rijavec E; Barletta G; Genova C; Biello F; Maggioni C; Grossi F
    Int J Mol Sci; 2015 Dec; 16(12):28765-82. PubMed ID: 26633390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
    Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
    Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
    Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
    Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted RNA sequencing with touch imprint cytology samples for non-small cell lung cancer patients.
    Seto K; Masago K; Fujita S; Haneda M; Horio Y; Hida T; Kuroda H; Hosoda W; Okubo KI
    Thorac Cancer; 2020 Jul; 11(7):1827-1834. PubMed ID: 32372482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma.
    Brisudova A; Skarda J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Jun; 164(2):127-132. PubMed ID: 32284620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.
    Velizheva NP; Rechsteiner MP; Wong CE; Zhong Q; Rössle M; Bode B; Moch H; Soltermann A; Wild PJ; Tischler V
    Cancer Cytopathol; 2017 Jan; 125(1):30-40. PubMed ID: 27636102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of different massive parallel sequencing platforms for mutation profiling in formalin-fixed and paraffin-embedded samples].
    Jiang RR; Wang YJ; Teng XD; Xiao L; Bu H; Ye F
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):591-596. PubMed ID: 30107663
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.
    Claerhout S; Lehnert S; Vander Borght S; Spans L; Dooms C; Wauters E; Vansteenkiste J; Weynand B; Deraedt K; Bourgain C; Vanden Bempt I
    Lung Cancer; 2022 Apr; 166():242-249. PubMed ID: 35378489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High success rate of first proficiency testing for RET fusions and RET mutations in lung and thyroid cancer samples by various methods.
    Siebolts U; Pappesch R; Bauer M; Dietmaier W; Ernst M; Haak A; Hartmann N; Ilm K; Kalbourtzis S; Krause T; Kazdal D; Schorle H; Utpatel K; Merkelbach-Bruse S
    Virchows Arch; 2024 Sep; 485(3):519-526. PubMed ID: 39120655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
    Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
    Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
    Cui W; Milner-Watts C; O'Sullivan H; Lyons H; Minchom A; Bhosle J; Davidson M; Yousaf N; Scott S; Faull I; Kushnir M; Nagy R; O'Brien M; Popat S
    Eur J Cancer; 2022 Aug; 171():44-54. PubMed ID: 35704974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Raez LE; Brice K; Dumais K; Lopez-Cohen A; Wietecha D; Izquierdo PA; Santos ES; Powery HW
    Clin Lung Cancer; 2023 Mar; 24(2):120-129. PubMed ID: 36585341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.